anti-CD33 CAR-T

Anti-CD33 CAR-T is a chimeric antigen receptor (CAR) T cell therapy engineered to target the CD33 antigen, a transmembrane receptor of the SIGLEC family highly expressed on myeloid cells and present in approximately 85–90% of acute myeloid leukemia (AML) cases. The therapy involves modifying patient-derived or donor-derived T cells to express a synthetic receptor that recognizes and binds to CD33 on leukemic cells. Upon binding, these engineered T cells become activated and mediate cytotoxicity against the malignant cells through cytokine release and direct killing mechanisms. Anti-CD33 CAR-T therapies are being developed for relapsed or refractory AML and have demonstrated preclinical efficacy in vitro and in animal models by reducing leukemic burden and improving survival. Clinical trials are ongoing to assess safety, feasibility, dose-limiting toxicities, response rates, overall survival outcomes, as well as unique challenges such as cytokine release syndrome (CRS), neurotoxicity (ICANS), tumor lysis syndrome (TLS), manufacturing complexity using viral vectors or healthy donor lymphocytes for allogeneic products[1][2][3][4][5].

Other names

anti-CD33 chimeric antigen receptor T cell therapyanti-CD-33 chimeric antigen receptor T cell therapyanti-CD 33 chimeric antigen receptor T cell therapyCD33-targeted CAR T cell therapyCD-33-targeted CAR T cell therapyCD 33-targeted CAR T cell therapy